Eylea® is the only approved anti-VEGF to successfully extend to 16-week treatment intervals in clinical trials with a T&E dosing regimen1,2
References:
- EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; August 2019. Return to content
- Ohji M, Ayame A, Takahashi K, Kobayashi M, Terano Y. Two different treat-and-extend dosing regimens of intravitreal aflibercept in Japanese patients with wet age-related macular degeneration: 96-week results of the ALTAIR study. Presented at: EURETINA 2018 Free Paper Sessions; September 2018; Vienna, Austria. Return to content
- Ohji M. Intravitreal aflibercept treat-and-extend dosing for wet age-related macular degeneration: 96-week ALTAIR results. Presented at: 122nd Annual Meeting of the American Academy of Ophthalmology; October 27-30, 2018; Chicago, IL. Return to content
- Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185. Return to content
